p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer

NCT00525200 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

170

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: 5-Fluoruracil, Cisplatinum
DRUG: Docetaxel

Sponsor

Daniela Kandioler

Collaborators

[object Object]
[object Object]